[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540547":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":32,"responsibleParty":48,"collaborators":22,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":22,"enrollmentInfo":61,"targetDuration":22,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":35,"whyStopped":22,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Aarhus University Hospital Skejby","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ATTRwt","EXPERIMENTAL","Dobutamine (Dobutrex®) infusion.",[13],"Drug: Dobutrex",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Dobutrex","Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug\u002Fkg\u002Fmin). Dobutamine dosage will only be increased to 40 ug\u002Fkg\u002Fmin in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug\u002Fkg\u002Fmin in participants with eGFR below 30 mL\u002Fmin\u002F1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.",[9],[21],"Dobutamine",null,[24,29],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Ali Hussein Jaber Mejren, MD","CONTACT","0045 91 65 18 48","alimej@clin.au.dk",{"name":30,"role":26,"phone":22,"phoneExt":22,"email":31},"Steen Hvitfeldt Poulsen, MD,PhD,DMSci","steepoul@rm.dk",[33],{"facility":34,"status":35,"city":36,"state":22,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Department of Cardiology, Aarhus University Hospital","RECRUITING","Aarhus","8200","Denmark","DK",{"type":41,"coordinates":42},"Point",[43,44],10.21076,56.15674,{"lat":44,"lon":43},[47],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"SPONSOR_INVESTIGATOR","Steen Hvitfeldt Poulsen","Professor, DMSc.","100540547","phase-1-haemodynamic-effects-of-dobutamine-in-patients-with-wild-type-transthyretin-amyloid-cardiomyopathy-attrwt-100540547",false,"NCT06318260","Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)","DobATTR","Inclusion Criteria:\n\n1. ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and\u002For endomyocardial biopsy.\n2. Treated with loop diuretics.\n3. New York Heart Association class II-IV.\n4. Age ≥ 65 years.\n5. Left ventricular ejection fraction (LVEF) \\\u003C 50 % and\u002For SVI assessed by echocardiography \\\u003C 35 ml\u002Fm2.\n6. Thorough oral and written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Moderate to severe aortic stenosis (participants with aortic sclerosis will not be excluded).\n2. Other significant valvular diseases.\n3. Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (\\\u003C 4 weeks).\n4. Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT).\n5. End stage renal disease (eGFR of less than 15 mL\u002Fmin\u002F1,73 m2).","ALL","65 Years",{"count":62,"type":63},15,"ESTIMATED","INTERVENTIONAL",[66,67],"PHASE1","PHASE2","The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main questions it aims to answer are:\n\n* What are the effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt.\n* Safety of dobutamine infusion in this patient population.\n\nParticipants will receive increasing doses of dobutamine infusion, and the effects on cardiac output and filling pressures will be assessed simultaneously by echocardiography and right heart catheterization.",[70],"ATTR Amyloidosis Wild Type",[72,73,74,75,21,76],"Cardiac amyloidosis","Inotropic","ATTR-CM","Transthyretin amyloid cardiomyopathy","wild type ATTR","2026-05-27",{"date":79,"type":80},"2026-06-01","ACTUAL",{"date":82,"type":80},"2024-04-08",{"date":84,"type":63},"2027-09",{"name":50,"class":6},1]